Skip to main content

Table 5 Adjusted risk of inappropriate empiric therapy, hospital mortality, excess LOS and costs

From: Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis

 

Marginal effect, CSE

Marginal effect, CRE

Adjusted relative risk ratio/excess days or costs (95% confidence interval)

P-value

Risk of IET

 Parse Model

11.8%

47.7%

3.95 (3.51, 4.46)

<0.001

 Propensity score (based on 100% CRE cases matched to CSE 1:1)

13.1%

55.8%

4.27 (3.64, 5.00)

<0.001

 Non-parse model

11.9%

47.7%

4.00 (3.48, 4.59)

<0.001

 

Marginal effect, non-IET

Marginal effect, IET

Adjusted relative risk ratio/excess days or costs (95% confidence interval)

P-value

Risk of death

 Hierarchical model

9.8%

11.0%

1.12 (1.03, 1.23)

0.013

 Propensity score (based on 96.4% IET cases matched to non-IET 1:1)

10.5%

11.9%

1.13 (1.01, 1.27)

0.030

Length of stay (days)

 Hierarchical model

8.2

13.4

5.2 (4.8, 5.6)

<0.001

 Propensity score (based on 96.4% IET cases matched to non-IET 1:1)

9.6

14.6

5.0 (4.4, 5.6)

<0.001

Hospital costs

 Hierarchical model

$20,508

$30,819

$10,312 ($9497, $11,126)

<0.001

 Propensity score (based on 96.4% IET cases matched to non-IET 1:1)

$22,005

$32,837

$10,831 ($9254, $12,409)

<0.001

  1. IET inappropriate empiric therapy, CSE carbapenem sensitive Enterobacteriaceae, CRE carbapenem resistant Enterobacteriaceae